Most patients maintain results effectively through a combination of the following: Monthly or bi-monthly maintenance IV sessions as recommended by your dermatologist Daily use of SPF 3050 broad-spectrum sunscreen - this is non-negotiable
Researchers planning multi-compound aging-research protocols sometimes examine Epithalon alongside one of the others
Certificates of Analysis (COAs) should include amino acid analysis, copper content determination (ICP-MS or AAS), and endotoxin testing for cell culture applications
The copper peptide angle deserves a closer look

this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults

Supports Sleep Regulation and Quality DSIP is best known for its involvement in sleep-related signaling